CINECA IRIS Institutional Research Information System

D'AGOSTINO, Mattia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.634
AS - Asia 3.587
NA - Nord America 3.185
SA - Sud America 546
OC - Oceania 142
AF - Africa 112
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.207
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.769
IT - Italia 1.801
CN - Cina 1.483
JP - Giappone 873
ES - Italia 462
GB - Regno Unito 395
DE - Germania 338
IN - India 299
FR - Francia 281
SG - Singapore 240
BR - Brasile 230
SE - Svezia 229
CA - Canada 217
MX - Messico 176
IE - Irlanda 170
TR - Turchia 150
HK - Hong Kong 141
AU - Australia 115
RU - Federazione Russa 111
NL - Olanda 110
CO - Colombia 109
PL - Polonia 83
BE - Belgio 77
CH - Svizzera 73
GR - Grecia 73
AR - Argentina 70
FI - Finlandia 68
PT - Portogallo 68
VN - Vietnam 68
TW - Taiwan 65
AT - Austria 58
ID - Indonesia 57
KR - Corea 47
DK - Danimarca 37
CL - Cile 35
IL - Israele 31
MA - Marocco 31
CZ - Repubblica Ceca 29
PE - Perù 29
UA - Ucraina 29
TH - Thailandia 28
NZ - Nuova Zelanda 27
EG - Egitto 25
RS - Serbia 23
BO - Bolivia 22
IR - Iran 22
HU - Ungheria 21
NO - Norvegia 21
HR - Croazia 20
EC - Ecuador 19
TN - Tunisia 18
VE - Venezuela 18
UY - Uruguay 14
RO - Romania 12
MK - Macedonia 11
DZ - Algeria 10
SA - Arabia Saudita 10
JO - Giordania 9
KZ - Kazakistan 9
MY - Malesia 9
CR - Costa Rica 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
BD - Bangladesh 7
BG - Bulgaria 7
ZA - Sudafrica 7
BA - Bosnia-Erzegovina 6
GT - Guatemala 6
NG - Nigeria 6
SI - Slovenia 6
SK - Slovacchia (Repubblica Slovacca) 5
TZ - Tanzania 5
MM - Myanmar 4
UZ - Uzbekistan 4
AM - Armenia 3
LT - Lituania 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
AL - Albania 2
CU - Cuba 2
CY - Cipro 2
EE - Estonia 2
GE - Georgia 2
LY - Libia 2
MQ - Martinica 2
NI - Nicaragua 2
PK - Pakistan 2
AZ - Azerbaigian 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
EU - Europa 1
GH - Ghana 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
QA - Qatar 1
RE - Reunion 1
TG - Togo 1
Totale 12.206
Salva come PNG Salva come JPEG
Città #
Florence 383
Beijing 212
Tokyo 210
Chandler 181
Redwood City 176
Shanghai 174
Dublin 162
Singapore 154
Turin 147
Fairfield 134
Torino 126
Madrid 121
Houston 119
Ottawa 106
Milan 98
Guangzhou 94
Ashburn 84
London 83
Ann Arbor 78
Rome 76
São Paulo 72
Nyköping 71
Seattle 70
Bologna 65
Barcelona 63
Hangzhou 62
Cambridge 60
Paris 60
Wilmington 60
Woodbridge 59
Nanjing 56
Istanbul 52
Central 51
Los Angeles 51
Jakarta 48
New York 48
Bogotá 47
Moscow 46
Mumbai 45
Frankfurt am Main 44
Princeton 44
Vienna 42
Chicago 41
Helsinki 40
Buenos Aires 37
Medford 36
Osaka 36
Chengdu 35
Hyderabad 35
Mexico City 35
Sydney 35
Tianjin 33
Taipei 31
Changsha 30
Hong Kong 30
Manchester 29
Toronto 28
Wuhan 28
Hebei 27
Athens 26
Boston 26
Chennai 26
Chongqing 26
Bari 25
Padova 25
Valencia 25
Dallas 24
Lima 24
Seoul 24
Brussels 23
Dearborn 23
Delhi 23
Auckland 22
Duncan 22
Catania 21
Fukuoka 21
Pisa 21
Pune 21
Yokohama 21
Zurich 21
Amsterdam 20
Ankara 20
Rochester 20
Ludhiana 19
Melbourne 19
Montreal 19
Munich 19
Santa Cruz 19
Atlanta 18
Boardman 18
Breda 18
Campi Bisenzio 18
Noto 18
Santiago 18
Berlin 17
Hanoi 17
Lisbon 17
Thessaloniki 17
Chiyoda-ku 16
Geelong 16
Totale 5.553
Salva come PNG Salva come JPEG
Nome #
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 3.101
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 1.737
MRD Assessment in Multiple Myeloma: Progress and Challenges 1.306
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 1.141
Plasma cell leukemia: update on biology and therapy 550
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors 457
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 381
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 298
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 273
Novel investigational drugs active as single agents in multiple myeloma 247
Determining treatment intensity in elderly patients with multiple myeloma 223
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 183
Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients 181
CD38 as an immunotherapeutic target in multiple myeloma 162
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? 155
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma 150
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 139
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 138
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma 131
Novel Immunotherapies for Multiple Myeloma 125
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 118
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma 114
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 112
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 106
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma 104
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score 87
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies 85
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma 79
Monoclonal antibodies to treat multiple myeloma: A dream come true 75
Anticorpi monoclonali bispecifici nel trattamento del mieloma multiplo 72
Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting 60
The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma 46
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status 36
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? 32
Tracking genetically engineered lymphocytes long-term reveals the dynamics of t cell immunological memory 27
Moving toward a tailored therapy in multiple myeloma 27
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma 24
MODULATION OF THE IMMUNE MICROENVIROMENT IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMABBASED THERAPY: TUMOR CELL-EXTRINSIC EFFECTS OF DARATUMUMAB TREATMENT 23
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma? 18
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 18
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 17
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop 16
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies 15
Predictors of Unsustained Minimal Residual Disease Negativity in Multiple Myeloma (MM) Patients 15
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 14
IMMUNE SUPPRESSION OF BONE MARROW Vγ9Vδ2 T CELLS BY BONE MARROW STROMAL CELLS (BMSC) IN MULTIPLE MYELOMA 14
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells 14
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma 12
Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment? 9
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research 8
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes 4
Totale 12.479
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.203
article - articoli 0
book - libri 0
conference - conferenze 529
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020535 0 0 0 37 37 43 37 59 118 80 72 52
2020/20211.432 55 67 95 108 136 118 123 109 111 134 138 238
2021/20221.599 121 100 98 130 142 104 118 107 88 139 171 281
2022/20233.207 100 150 142 292 237 335 319 290 321 255 349 417
2023/20244.263 339 420 335 402 353 343 369 375 131 363 442 391
2024/20251.196 274 341 379 202 0 0 0 0 0 0 0 0
Totale 12.479